BioMarin Pharma(BMRN.US)

Last Updated 19:00:00 ET
longbridge loading

BioMarin plans FDA filing in Q3 2026 for Voxzogo in hypochondroplasia

PUBT·
US
BMRN
+0.78%
US
IHE
+0.84%
US
PBE
+1.60%
PUBT·
US
BMRN
+0.78%
US
IHE
+0.84%
US
PBE
+1.60%

BioMarin drug acquired in buyout misses goal in rare disease study

biopharmadive·
US
BMRN
+0.78%
biopharmadive·
US
BMRN
+0.78%

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia | BMRN Stock News

StockTitan·
US
BMRN
+0.78%
StockTitan·
US
BMRN
+0.78%

BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint

WorldPharmaceuticals·
US
BMRN
+0.78%
US
ARKG
+5.05%
US
XBI
+3.88%
WorldPharmaceuticals·
US
BMRN
+0.78%
US
ARKG
+5.05%
US
XBI
+3.88%

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

Simplywall·
US
BMRN
+0.78%
US
XBI
+3.88%
US
SBIO
+3.75%
Simplywall·
US
BMRN
+0.78%
US
XBI
+3.88%
US
SBIO
+3.75%
© 2026 Longbridge｜Disclaimer